<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01196481</url>
  </required_header>
  <id_info>
    <org_study_id>ILBS PHT-04</org_study_id>
    <nct_id>NCT01196481</nct_id>
  </id_info>
  <brief_title>Carvedilol + VSL#3 Versus Endoscopic Variceal Ligation for Primary Prophylaxis of Esophageal Variceal Bleeding in Cirrhotic Patients Non Responder to Carvedilol.</brief_title>
  <official_title>A Prospective,Open Labeled, Randomized Controlled Trial Comparing Carvedilol + VSL# 3 Versus Endoscopic Variceal Ligation for Primary Prophylaxis of Esophageal Variceal Bleeding in Cirrhotic Patients Non Responder to Carvedilol.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Liver and Biliary Sciences, India</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Liver and Biliary Sciences, India</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients of cirrhosis will be enrolled who have large esophageal varices, which have never
      bled. After successful screening baseline hepatic venous pressure gradient (HVPG) will be
      measured. Tablet carvedilol 3.125 mg BD for 1 week will be started. It will be increased to
      6.25 mg BD and continued for next 7 weeks. After completion of 8 weeks the hepatic venous
      pressure gradient (HVPG) will again be measured to find out responders (hepatic venous
      pressure gradient â‰¥20% reduction from baseline or absolute value of hepatic venous pressure
      gradient &lt;12 mm Hg) and non responders (hepatic venous pressure gradient &lt;20% reduction).The
      responders will be excluded from the study while the non responders will be randomize into
      carvedilol+VSL#3 versus Endoscopic Variceal Ligation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Development of first variceal bleeding</measure>
    <time_frame>1 Year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>1 Year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in Portal pressure</measure>
    <time_frame>1 Year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to bleed</measure>
    <time_frame>1 Years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>1 Year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Carvedilol+VSL#3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tablet Carvedilol 6.25 mg BD + VSL#3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Endoscopic Variceal Ligation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Endoscopic Variceal Ligation every 3-4 weeks till variceal ligation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carvedilol+VSL#3</intervention_name>
    <description>Tablet Carvedilol 6.25 mg BD &amp; capsule VSL#3 1 TDS for 2 year</description>
    <arm_group_label>Carvedilol+VSL#3</arm_group_label>
    <arm_group_label>Endoscopic Variceal Ligation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endoscopic variceal ligation</intervention_name>
    <description>In the Endoscopic Variceal Ligation arm, Endoscopic Variceal Ligation will be performed using multibander devices by senior fully trained endoscopists or under their direct supervision. Varices will be banded starting at the gastroesophageal junction moving proximally upward in a spiral fashion. Patients will undergo Endoscopic Variceal Ligation every 3-4 weeks until eradication. Eradication is defined as the absence of varices or presence of grade I esophageal varices. Following eradication, the interval for the next endoscopy will be every 3 months to look for recurrence of varices. Endoscopic Variceal Ligation sessions would be repeated for the recurrent varices if they are sufficiently large.</description>
    <arm_group_label>Endoscopic Variceal Ligation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients of cirrhosis with portal hypertension aged 18 to 75 years who have large
             esophageal varices with or without red color signs and have not bled previously.

        Exclusion Criteria:

          -  Any contra-indication to beta-blockers

          -  Coagulopathy with INR &gt;1.8 at the time of enrollment

          -  Any Endoscopic Variceal Ligation or sclerotherapy within last 3 months

          -  Any past history of surgery for portal hypertension

          -  Significant cardio or pulmonary co-morbidity

          -  Any malignancy

          -  Refusal to participate in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shiv Kumar Sarin, MBBS, MD, DM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Liver &amp; Biliary Sciences (ILBS)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Liver &amp; Biliary Sciences (ILBS)</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110 070</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 4, 2010</study_first_submitted>
  <study_first_submitted_qc>September 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2010</study_first_posted>
  <last_update_submitted>August 14, 2017</last_update_submitted>
  <last_update_submitted_qc>August 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carvedilol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

